This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Insiders Love Right Now

United Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A stock in the biotechnology and drugs complex whose insiders are snapping up a decent amount of shares is United Therapeutics (UTHR), a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients. Insiders are buying into weakness here since the stock is off by over 30% in 2011.

United Therapeutics has a market cap of $2.42 billion and an enterprise value of $2.01 billion. This stock trades at a cheap valuation; its trailing price-to-earnings is 13.87, and its forward price-to-earnings is 10.44. This is a cash-rich company, with a total cash position of $694.60 million and total debt of $317.47 million. After you back out the debt, United Therapeutics has $377.23 million in cash on their books.

The CEO and director just bought 12,994 shares, or $539,178 worth of stock, at $40.98 to $42.19 per share. The same CEO also bought over $2 million worth of stock since the start of December.

From a technical standpoint, UTHR is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock hit a low in October of $36.55 a share and since then it has rallied strong to its current price of just over $41.40 a share. As long as UTHR can hold above its 50-day moving average of $41.10, then the stock sets up to test a near-term breakout.

If you're bullish on UTHR, I would get long once it breaks out above some overhead resistance at $42.68 and $44.96 on high-volume. Look for a high-volume move above those levels that hits near or above its three-month average action of 1,364,600 shares. If we get that action, then this stock could setup to make a run towards $50 to $52.95 (the 200-day) a share. I would simply use a mental stop that's a few percentage points below the 50-day if you get long UTHR in the near future.

United Therapeutics shows up on a recent list of 5 Biotech Stocks for 2012 and was featured recently in " 5 Low-Risk Stocks to Buy for 2012."

5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs